Table 1.

Demographics: The clinical and pathologic features of 119 patients with advanced solid tumors who received entrectinib on either phase I trial (ALKA-372-001 or STARTRK-1) are summarized

ALKA-372-001 (n = 54)STARTRK-1 (n = 65)Total (n = 119)
Age, years, median (range)53 (22–77)57 (18–80)55 (18–80)
Sex, male/female (%)44/5648/5246/54
ECOG performance status, n (%)
 030 (56)22 (34)52 (44)
 121 (39)41 (63)62 (52)
 22 (4)2 (3)4 (3)
 Unknown1 (2)01 (1)
Prior systemic therapies, n (%)
 006 (9)6 (5)
 1–2015 (23)15 (13)
 3–43 (6)25 (39)28 (24)
 >451 (94)19 (29)70 (59)
Prior ROS1/ALK inhibitors, n (%)10 (19)22 (34)32 (27)
Prior immunotherapy, n (%)04 (6)4 (3)
Tumor type, n (%)
 NSCLC35 (65)36 (56)71 (60)
 Gastrointestinal tract9 (17)9 (14)18 (15)
 CNS4 (7)1 (2)5 (4)
 Head and neck1 (2)4 (6)5 (4)
 Othera5 (9)15 (23)20 (17)
  • NOTE: Most patients had an ECOG performance status of 0 or 1 and were heavily pretreated with three or more prior anticancer therapies. Patients with a wide range of solid tumors were treated.

  • Abbreviation: CNS, central nervous system.

  • aOther tumor types: breast, cholangiocarcinoma, melanoma, neuroblastoma, neuroendocrine ovarian, pancreatic, prostate, renal cell carcinoma, sarcoma, squamous skin cancer, unknown primary.